Healthy
Conditions
Brief summary
The study investigates the effect of glucagon-like peptide receptor 1 agonist, liraglutide, on insulin secretion. Study hypothesis: the effect of liraglutide on insulin release may change after repeated administration. The effect of liraglutide on insulin release will be tested using graded glucose infusion test (GGIT) in healthy volunteers. GGIT will be performed without medication and repeated 12 hours after first dose of liraglutide and after 3 weeks of treatment with liraglutide.
Interventions
DRUGLiraglutide
Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated. GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection).
Sponsors
University of Tartu
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Weight 50-100 kg
Exclusion criteria
* Chronic disease * Concomitant drug use * Pregnancy or lactation * Fasting glucose \>6 mmol/L.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the glucose-sensitivity of the beta cells | baseline, first dose, after 3-weeks on treatment | Graded glucose infusion test will be used to create insulin secretion rate- plasma glucose curve. The primary outcome is the change of the slope of the curve from baseline after acute administration of liraglutide compared to the repeated administration (after 3-weeks of treatment). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effects on adrenal hormones | baseline, acute administration, 3 weeks | change in ACTH/cortisol levels and renin / aldosterone levels after acute and repeated administration of liraglutide. |
Countries
Estonia
Outcome results
None listed